Introduction
Gastric cancer (GC) was the third leading cause of cancer death in 2012 for both men and women, with 723 000 recorded deaths accounting for 8.8% of cancer deaths worldwide [1] . The highest incidence and mortality rates for both men and women were reported for Eastern and Western Asia, Latin America and some Eastern European countries [2] . The incidence rates (cases/ 100 000 people) for men in Japan's Miyagi Prefecture and Korea of 66.7 and 64.6, respectively, were both more than twice those of the next highest incidence rate of 30.4 that was reported for the Golestan province of Iran. For women, the incidence rates in Japan of 22.8 and Korea of 25.4 were 60% higher than the next highest rates, which were in Ecuador and Costa Rica and were 15.0 for each country [2] . Thus, GC is a major healthcare challenge across Asia and particularly Eastern Asia.
GC is classified as either cardia GC (CGC) or non-cardia GC (NCGC) depending on the site/location within the stomach (proximal or distal), and the incidence of each subtype is influenced by regional variations in the risk factors for each. The highest regional rates for both CGC and NCGC are in Eastern and Southeastern Asia [3] . Chronic infection with Helicobacter pylori (H. pylori) accounts for $90% of the cases of distal NCGC worldwide [4] . Other influences are thought to include availability of fresh fruits and vegetables, dietary patterns and methods of food preservation [4] .
However, since the middle of the 20th century, both the incidence and mortality rates for GC have been declining in North America, high-income countries in Europe and more recently in many other countries, including those in Asia. These trends have been dominated by a decline in the occurrence of NCGC and are thought to be attributable to the decline in H. pylori infections [5] due to improved sanitation and the availability of antibiotics. In addition, the availability of fresh produce, less reliance on saltpreserved foods [6] , and a reduction in smoking may also have contributed to the declines [7] . Conversely, the rates of CGC and cancers of the gastro-oesophageal junction (GEJ) are increasing in the United States, and many European countries [8] [9] [10] , which possibly reflects the increase in visceral obesity and gastrooesophageal reflux in the populations of these countries. Although the clinical behaviour of GC is distinct in each country as stated above, establishing an integrated consensus for the treatment and management of patients with GC across continents is thought to be valuable.
Guidelines for the prevention, screening, treatment and management of patients with GC in Asia have been published previously [11] [12] [13] [14] [15] [16] [17] . The ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with GC have also recently been published [18] , and a decision was taken by the ESMO and JSMO to use these latest ESMO guidelines to develop guidelines for the treatment and management of metastatic GC (mGC) in patients of Asian ethnicity. As a result, a 1-day, face-toface, working meeting was convened on the 22 July 2018 in Kobe Japan immediately after the 16th Annual Meeting of the JSMO, to finalise this process. Finalisation of the Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer took place at the same meeting and will be published separately [19] .
Methodology
This Pan-Asian adaptation of the ESMO guidelines was prepared in accordance with the processes and format developed for the preparation of the first Pan-Asian adapted ESMO guidelines for the management of patients with metastatic colorectal cancer [20] .
Composition of expert panel
The international panel of experts was selected according to their demonstrable knowledge of the field of gastric and oesophageal cancer patient treatment and management in terms of publications and/or their participation in the development of national or international treatment guidelines. More specifically this included 10 expert members of the JSMO, 8 expert members from the ESMO and 2 experts each from the oncological societies of China (CSCO), Korea, (KMSO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). Only 2 of the 10 expert members from the JSMO (EB and KK) were allowed to vote on the recommendations together with the 2 experts from each of the 5 other Asian oncological societies.
Provisional statements
A set of preformulated topics and eight recommendations for the treatment of mGC, based on those in the latest ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of GC [18] , were circulated, before the meeting, to each of the 12 Asian experts representing the 6 Asian oncological societies to gather their comments and input on each of the recommendations. Specific emphasis was placed on current agreement with the published data used for the recommendations in their countries, including the data generated from studies in Asian patients, together with the applicability of novel clinical study data to current practice in their countries. Consideration was to be made independently of the actual access to, and availability of, the respective diagnostic tools and treatments in their respective countries. The Asian experts were specifically asked 'Is this recommendation adaptable for use in your country?'. The 12 experts were also asked to provide details of the reasoning behind their responses and the relevant references to support their decisions.
Voting process
A modified Delphi process was used to develop each individual statement before the final discussion and final voting process at the face-to-face working meeting in Kobe. The 12 Asian experts were asked to vote based on the evidence available, on a scale of A to E, where A ¼ accept completely; B ¼ accept with some reservation; C ¼ accept with major reservation; D ¼ reject with some reservation and E ¼reject completely (Table 1 ). An adapted version of the 'Infectious Diseases Society of America-United States Public Health Service Grading System' [21] was used to define the level of evidence and strength (grade) of each recommendation proposed by the group, as for all of the ESMO Consensus and ESMO Clinical Practice Guidelines (Table 1) , and are given in the text in square brackets after each recommendation together with details of the levels of agreement. Most statements on the level of agreement were based on peer-reviewed manuscript data or peer-reviewed abstract data, although statements made based on expert opinion were also considered to be justified standard clinical practice by the experts and the JSMO and ESMO faculty. The remaining 16 experts, 8 from the JSMO and 8 from the ESMO were there to offer expert opinion at the face-to-face meeting, with 1 non-voting member of the JSMO (KM) and 1 nonvoting member of the ESMO (EVC) co-chairing the meeting.
Final consensus statements
A consensus was considered to have been achieved when !80% of experts voted to accept completely or accept with reservation a specific recommendation. A recommendation was considered to have been rejected when >80% of the voting members indicated 'reject completely' or 'reject with reservation'. For recommendations where a consensus was not reached initially the entire panel of 12 Asian experts was invited to discuss and modify the recommendation(s) at the face-to-face meeting, and a second round of voting was conducted. If still no consensus could be reached, the recommendation could be modified one more time, and a third and last vote was conducted to determine the definitive acceptance or rejection of a recommendation.
Results
In the initial pre-meeting survey, the 12 experts representing the oncological societies of the 6 Asian countries (Japan, China, Korea, Malaysia, Singapore and Taiwan) reported on the applicability of the eight recommendations for the management and treatment of mGC from the 2016 ESMO Clinical Practice Guidelines [18] . These recommendations were made in the categories: and for the purposes of the evaluation and voting process were numbered 1-8 with the subcategories assigned a letter code (a, b, c, etc.). An unqualified response of YES in the pre-meeting survey equated with 'accept completely' in the final voting, i.e. A ¼ 100%. Following the initial survey, agreement was not reached between the 6 Asian countries on recommendations 2, 4a, c and d, 5a and b, 6c and 8a (supplementary Table S1 , available at Annals of Oncology online). At the face-to-face meeting in Kobe, the 12 Asian experts in the treatment of GC were asked to discuss and to vote again on these recommendations. Voting on recommendations 1a, 3, 4 b, 6a and e (the original 'recommendation 6d'), 7 and 8b was not necessary, although additional recommendations concerning biomarkers were made. The final levels of agreement and levels of evidence and strength of support recorded for each ESMO recommendation by the Asian panel members are provided in the text below, beside each of the eight recommendations. Where changes to the original text have been made, including the addition of new subcategories and in some cases the complete revision of an existing recommendation, these are emphasised in bold both in the main text of the article and Table 2 , and reference made to the change in the text as * Depending on the prevalence of UGT1A1 polymorphisms per country a lower irinotecan threshold dose for UGT1A1 genotyping may be used.
All 12 Asian experts agreed with and accepted completely [A ¼ 100%] 'recommendation 1a' above that the human epidermal growth factor receptor-2 (HER2) status (HER2 positivity) of the tumours of all patients with mGC should be established at the time of diagnosis. This opinion was based on data from the randomised, phase III ToGA trial [22] in which HER2 positivity (increased HER2 expression or HER2 gene amplification) was observed in 22.1% of the tumour samples analysed from patients with advanced GC or advanced cancer of the GEJ [23] . The rates of HER2 positivity were similar for European and Asian patients at 23.6% and 23.9%, respectively [23] . Trastuzumab plus chemotherapy was shown to significantly improve overall survival (OS) in patients with HER2-positive tumours compared with those who received chemotherapy alone (OS 16.0 versus 11.8 months, hazard ratio 0.65, 95% confidence interval 0.51-0.80) and is recommended in combination with chemotherapy for the treatment of patients with HER2 immunohistochemistry (IHC) 2þ with fluorescence in situ hybridisation-positive or IHC 3þ disease [Magnitude of Clinical Benefit Scale (MCBS) 5] [22] . This benefit of trastuzumab in HER2-positive patients was confirmed for Asian patients in a subgroup analysis of 101 HER2-positive Japanese patients included in the ToGA trial [24] , and in a randomised, controlled trial of 85 Chinese patients [25] . Comparable antitumour activity was also seen in the non-randomised phase II Japanese HERBIS-1 study in which patients with HER2-positive tumours were treated with trastuzumab tri-weekly in combination with tegafur/gimeracil/oteracil (S-1) and cisplatin [26] . Assessment of HER2 positivity with a view to selecting patients for treatment with a trastuzumab-containing regimen is used routinely in Japan, China, Korea Taiwan and Singapore for patients with inoperable mGC, and is recommended by the Japanese gastric treatment guidelines [12] , CSCO, the Chinese Anticancer Society, the Korean Clinical Practice Guidelines [14, 15] and the Taiwan Cooperative Oncology Group (TCOG) Clinical Practice Guidelines for GC. For details of further trials, see 'recommendation 7'.
The experts also agreed completely [A ¼ 100%] with the addition of 'recommendation 1b' above, most of the wording for which was taken from the Pan-Asian adapted ESMO guidelines for the management of patients with metastatic colorectal cancer [20] . The enzyme activity of UGT1A1 is known to be closely associated with genetic polymorphisms of UGT1A1. In Asian patients, the frequency of the UGT1A1 *28 variant is much lower than that in Caucasian patients, whilst the converse is true for the UGT1A1 *6 variant [27] . Some Japanese studies [28, 29] have reported that UGT1A1 *6 or *28 homozygous genotypes increase the incidence of severe neutropenia but not diarrhoea, and Cheng et al. have verified the association between UGT1A1 *6/*6 alleles and severe neutropenia among Asian populations in a meta-analysis [30] . It is estimated that $10% of Japanese patients are either homozygous or simultaneously heterozygous for the UGT1A1 *6 or *28 alleles associated with irinotecan-induced toxicities [31, 32] . Thus, for patients known to have such a genetic background, irinotecan dose reduction is strongly recommended, and for patients with homozygous genotypes, the maximum tolerated dose is considered to be 150 mg/m 2 [29, 30] . In addition, the Pan-Asian experts proposed that gastric tumours may be optionally tested for microsatellite instability (MSI) and mismatch repair deficiency (dMMR) with a view to predicting the clinical benefit of immune check-point inhibitors (ICIs), once they become available to patients [33] . At the present time, the opinion is that the tumours of patients with mGC do not need to be routinely tested for programmed death-ligand 1 (PD-L1), tumour mutation burden (TMB) and Epstein Barr virus (EBV). However, PD-L1, TMB and EBV may be considered as potential biomarkers for the use of ICIs in the future [34] [35] [36] [37] . Table S1 , available at Annals of Oncology online) and a modification to the text to include the word ideally (see bold text above). HDGC accounts for 1%-3% of the total GC incidence worldwide [38] . However, such incidence data are not available for Asia. In Japan, HDGC families with a CDH1 germline mutation or a large deletion in the CDH1 gene have been reported [39] [40] [41] . However, overall in the case of the 6 Asian countries represented by the experts, HDGC is considered to be very rare and access to a geneticist who specialises in GC is difficult in most of the six countries.
Recommendation 3: diagnosis and pathology The Asian experts accepted completely [A ¼ 100%] the ESMO recommendation on 'diagnosis and pathology' taken from the ESMO 2016 guidelines [18] . Patients in Asian countries are frequently diagnosed with earlier stage disease than patients in nonAsian countries. In Japan and Korea where the incidences of GC are the highest in the world, national screening programmes for routine GC screening are available [2] . Ninety percent of GCs are adenocarcinomas which are subdivided according to histological appearance into diffuse (undifferentiated) and intestinal (welldifferentiated) carcinomas according to the Lauren classification [42] . The Japanese Classification of Gastric Carcinoma (JCGC) (15th edition or 3rd edition in English [43] ) is also widely used in Japan in terms of histological diagnosis and differs in some respects from the WHO and Lauren classifications, e.g. poorly cohesive carcinoma in the WHO classification, includes non-solid type poorly differentiated adenocarcinoma and signet-ring cell carcinoma in JCGC criteria. The Cancer Genome Atlas (TCGA) molecular subtyping project has identified four principal GC subtypes [44, 45] . Comprehensive profiling of GCs from 207 Japanese patients with a 435-gene panel showed Japanese patients to be consistent with these four molecular subtypes but to have significantly fewer tumours with MSI (8% versus 21%) and more genome stable tumours (30% versus 20%) than the TCGA GC classification. In addition, actionable genetic alterations were not specific and were widely observed throughout the four TCGA subtypes [46] . The Asian Cancer Research Group (ACRG) has also classified patients with GC into four subtypes according to molecular profiling [47] . Both the TCGA and ACRG classifications have identified a group of MSI-high tumours, but differ in the other subtypes. The MSI-high and EBV-positive GC subtypes has been shown to be highly sensitive to immunotherapy, whilst patients with the ACRG epithelial-to-mesenchymal transition GC subtype may not respond to single-agent antiprogrammed death-1 (PD-1) receptor therapy [36] . In addition, the ACRG subtypes have prognostic value, but the TCGA GC subtypes do not. Three major subtypes of GC have been identified in patients from Singapore and Australia [48] . As for the ESMO 2016 Guidelines [18] , the current guidelines document does not consider rarer gastric malignancies, such as gastrointestinal stromal tumours, lymphomas and neuroendocrine tumours. 4d. DCF in a 3-weekly regimen was associated with improved OS, but also added significant toxic effects including increased rates of febrile neutropenia [I, C]. This recommendation was to be removed. These recommendations and the adaptations to the original ESMO 2016 recommendations were based on the fact that systemic chemotherapy has been shown to improve survival and quality of life compared with BSC alone, in patients with GC [49] [50] [51] . Typically in Asia, first-line therapy is a platinum/fluoropyrimidine doublet based on the demonstrated improvement in response and survival compared with fluoropyrimidine alone in Asian patients with GC [52, 53] (Figure 1 ). Both cisplatin and oxaliplatin have been shown to have similar efficacy as components of doublet and triplet regimens for the treatment of Western and Asian patients with mGC [54] [55] [56] [57] . However, oxaliplatin is the preferred choice due to its favourable safety profile and ease of administration. Of the three available fluoropyrimidines, 5-fluorouracil (5-FU), capecitabine and S-1, capecitabine tends to be favoured due to its ease of administration and its demonstrated non-inferiority to infusional 5-FU in triplet and doublet regimens [55, 58, 59] . Although, 5-FU is also routinely used in Asian countries, especially for patients who cannot manage oral intake or have massive ascites. Subset analyses of the data from the AVAGAST and ToGA trials also showed capecitabine plus cisplatin to be well tolerated in Japanese patients [60] . A meta-analysis found no differences in OS or progression-free survival (PFS) for capecitabine-based versus 5-FU-based regimens, S-1-based versus 5-FU-based regimens and S-1-based versus capecitabine-based regimens [61] . Moreover, the effects were similar in Asian and Western patient subgroups [61] . S-1 has similar efficacy to capecitabine both as a single agent [62] and in platinum doublets [61, 63] but with a lower frequency of relevant adverse events.
The triplet regimen of docetaxel, cisplatin, 5-FU (DCF) has been shown to improve OS when compared with the doublet regimen of cisplatin and 5-FU, however, its use is limited due to significant toxicity [64] . A small randomised phase II study of modified DCF (mDCF) compared with DCF [65] demonstrated an improvement in survival for mDCF, but although the toxicity was less, it still remained significant with a 22% hospitalisation rate. However, recent data from the Japanese phase III JCOG1013 trial show the addition of docetaxel to doublet S-1 and cisplatin chemotherapy to fail to improve OS in patients with advanced GC [66] . mDCF therefore may be considered in selected patients, supported by two recent Asian trials [67, 68] .
Also, although a meta-analysis has demonstrated a significant benefit from the addition of an anthracycline to a platinum/fluoropyrimidine doublet [59] , the addition of anthracyclines to a platinum/fluoropyrimidine doublet did not lead to improved response or survival in Asian patients [69] , and is not recommended. Trials of non-platinum containing fluoropyrimidine doublets with docetaxel [70] or paclitaxel [71] conducted in Asian patients or irinotecan in trials conducted in Western patients [72, 73] have also shown similar efficacy to doublet platinum/fluoropyrimidine combinations. However, these doublets are not routinely used in Asia, as taxanes and irinotecan are typically reserved for use in the second-and third-line treatment settings. guidelines [18] . The revisions were made to reflect the current situation for the treatment of mGC in Asian patients. It was agreed unanimously that 'recommendation 5b' should be deleted as it was considered to have been incorporated into 'recommendation 4a-2'. In Asia, the regimens for the treatment of elderly patients with mGC have evolved based on the results of phase II trials in elderly patients and subgroup analyses of elderly patients included in phase III trials. A Japanese phase II trial has shown the median PFS and OS for patients with mGC aged >75 years achieved with single-agent S-1 [74] to be comparable with those achieved in the S-1 treatment arm of the phase III SPIRITS trial in patients aged 20-74 years [53] . A subgroup analysis of the Japanese phase III JFMC36-0701 trial showed a similar benefit for patients aged !75 and <75 years treated with S-1 [75] , whilst a Korean phase II trial in patients aged !65 years showed capecitabine and S-1 to be equally effective [62] . In Taiwan, high-dose fluorouracil and leucovorin therapy has been widely used for over 20 years, and is widely used for the treatment of elderly patients [17, 76, 77] and is listed in the TCOG GC Guidelines for Taiwan [78] (also cited in reference [17] ), and in the National Taiwan University Hospital GC guidelines. Dose attenuated capecitabine oxaliplatin (CAPOX) [79] and 5-FU, leucovorin and oxaliplatin (FOLFOX) [80] regimens have also shown acceptable toxicities and similar efficacies to studies with standard doses in two Chinese phase II trials in elderly patients. Furthermore, a randomised, phase III, Korean study in elderly patients !70 years showed CAPOX to be superior to capecitabine alone in terms of PFS and a Japanese trial showed S-1 and oxaliplatin (SOX) to be superior to S-1 and cisplatin in terms of PFS and OS in elderly patients !70 years of age [81, 82] . The fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) combination regimen developed in Europe [54] was not superior to fluorouracil, leucovorin, oxaliplatin (FLO) in patients with mGC or in those patients aged !70 years [83] or to FOLFOX in a Chinese trial in patients aged !65 years [68] , and its use has not been developed in Asia. 6d. In patients with symptomatic locally advanced or recurrent disease, hypofractionated radiotherapy is an effective and well-tolerated treatment modality that may palliate bleeding, obstructive symptoms or pain [A ¼ 100% and III, B].
All 12 Asian experts agreed with and accepted completely [A ¼ 100%] 'recommendation 6a' and the deletion of 'recommendation 6b', with the proposal that patients with mGC who have progressed on first-line treatment are assigned to secondline treatment and care according to the treatment options presented in Figure 1 . These options are based on the observations that irinotecan or docetaxel monotherapy have been shown to be superior to BSC in individual trials in both Western and Asian patients [84] [85] [86] [87] , and also in a meta-analysis [88] . A randomised phase III trial directly comparing irinotecan and paclitaxel as second-line therapy in patients with advanced GC showed them to have similar efficacy [89] . Whilst, nab-paclitaxel (not approved for GC except for Japan) has been shown to be noninferior to paclitaxel in an open-label, randomised phase III trial [90] . However, paclitaxel plus ramucirumab is now the preferred second-line treatment option for patients with mGC and an Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1, based on the results of the phase III RAINBOW trial conducted across 27 countries worldwide [91, 92] , in which $35% of the patients were of Asian ethnicity [93] (ESMO MCBS 2). A Japanese study has also investigated nab-paclitaxel and ramucirumab in a singlearm phase II trial and reported promising activity [94] . Ramucirumab monotherapy is also one of the second-line options (Figure 1 ) based on the results of the randomised phase III REGARD trial in which $16% of the patients were of Asian ethnicity [95] (ESMO MCBS 1). Today, irinotecan [86, 87] or taxane monotherapy [84, 86, 90] is considered an alternative second-line treatment option for patients with mGC who are not candidates for ramucirumab treatment or where ramucirumab is not available. The experts agreed completely [A ¼ 100%] with the new revised 'recommendation 6b' that for patients treated with chemotherapy which was stopped before progression and who have not progressed within 3 months it may be appropriate to consider the reintroduction of the same drug combination. The experts also accepted completely the new 'recommendation 6c' [A ¼ 100%]. Docetaxel and irinotecan have also been shown to be effective as salvage therapies [85] . Thus, for patients with disease progression after second-line therapy with a taxane þ/Àramucirumab, irinotecan therapy is an option. Nivolumab, a monoclonal antibody that binds to the PD-1 receptor, is also recommended as monotherapy for treatment in the third-or later-line settings based on the results of the ATTRACTION-2 trial in mGC ECOG PS 0-1 patients, who were refractory or intolerant to two or more previous lines of chemotherapy, conducted in Japan, Korea and Taiwan [96] [not approved by the European Medicines Agency (EMA)]. Trifluridine/tipiracil (FTD/TPI, TAS-102) has demonstrated efficacy with an acceptable toxicity profile in a Japanese phase II study in patients with advanced pre-treated GC [97] . More recently, FTD/TPI was shown to produce a 31% reduction in the risk of death compared with placebo in patients with heavily pre-treated advanced or mGC in the multinational, phase III TAGS trial [98] (not approved by the EMA). In a Chinese phase III trial, apatinib, a vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, showed a significant survival benefit over placebo in the third-and later-line settings [99] and is approved for use in China. Monotherapy with pembrolizumab, another monoclonal antibody that binds to the PD-1 receptor, has shown promising activity and manageable safety in a global, single-arm phase II trial (KEYNOTE-059) in patients with advanced GEJ cancer or GC who had previously received at least two lines of prior systemic therapy [100] . This led to the United States Federal Drug Administration (FDA) approving pembrolizumab for the treatment of mGC that expresses PD-L1 [combined positive score (CPS) !1] and has progressed on or after two or more previous lines of therapy including platinum-and fluoropyrimidine-containing chemotherapy (not approved by the EMA). Pembrolizumab did not significantly improve OS compared with paclitaxel as second-line therapy for mGC with PD-L1 (CPS !1) in the phase III trial (KEYNOTE-061) [37] . Subgroup analyses suggest that the treatment effect of pembrolizumab might be more pronounced in patients with a better PS, and tumours with greater levels of PD-L1 expression, and MSI [37] , all of which will be evaluated in ongoing trials in the first-line setting.
Finally, palliative radiotherapy may be an option for patients with symptomatic, locally advanced or recurrent disease [101] [102] [103] [104] [105] [106] [107] The Asian experts accepted this 'recommendation' completely [A ¼ 100%] consistent with 'recommendation 1a' above, and based on the data from the ToGA trial [22] [23] [24] , a Chinese randomised controlled trial [25] , several Japanese phase II trials [26, 108, 109] and one Korean trial [110] . A Japanese phase II trial has shown high antitumour activity and manageable toxicity for trastuzumab plus S-1 in elderly patients [111] . A non-randomised Japanese trial has also shown trastuzumab combined with paclitaxel to be well tolerated with promising activity, in the secondor later-line treatment of trastuzumab-naïve patients [112] . However, trastuzumab beyond progression second-line in patients who were previously treated with trastuzumab failed to improve PFS in the Japanese WJOG 7112G trial [113] .
As stated previously in 'recommendation 3' above, four principal GC subtypes have been identified [44] [45] [46] [47] . Each molecular subtype is enriched for selected molecular abnormalities [18] , which include enriched copy numbers of key receptor tyrosine kinase genes, such as those for HER2, epidermal growth factor receptor (EGFR), fibroblast growth factor receptor-2 and hepatocyte growth factor (HGF) receptor (MET) or MSI-high/dMMR. These findings have potentially important implications for the development of targeted therapeutic (personalised medicine) approaches in the treatment of patients with mGC. As mentioned previously (recommendation 1) gastric tumours may be optionally tested for MSI and dMMR with a view to predicting the clinical benefit of ICIs. For example, the previously treated MSI-high advanced cancer patients in the KEYNOTE-164 and KEYNOTE 158 trials [114, 115] , and the gastric and GEJ patients in the KEYNOTE-061 trial [116] , showed high response rates to pembrolizumab. Therefore where nivolumab and FTD/TPI are available as 3 rd -line therapies, for patients with MSI-high tumours, nivolumab would be the preferred option (Figure 1) .
Indeed, PD-L1, TMB and EBV may be considered as potential biomarkers for the use of ICIs in the future [34] [35] [36] [37] . PD-L1 in particular has been investigated as a biomarker for ICIs such as pembrolizumab and nivolumab, monoclonal antibodies that bind to the PD-1 receptor. However, the phase III KEYNOTE-061 study of pembrolizumab versus paclitaxel in patients with CPS !1 advanced GC or cancer of the GEJ (mentioned previously under 'recommendation 6' and in relation to MSI above) [37] , failed to meet its primary end point and has to be considered as a negative trial, and as a result pembrolizumab is not recommended for the treatment of patients with mGC in this treatment setting. Whilst, nivolumab in a randomised placebo-controlled, phase III trial (ATTRACTION-02) [96] , in Asian patients with advanced GC or cancer of the GEJ who had previously received at least two lines of prior systemic therapy, showed a statistically significant benefit in OS (P < 0.0001) compared with placebo regardless of PD-L1 expression. At the present time, none of the ICIs have been approved by the EMA for GC. Randomised phase III trials of anti-EGFR and anti-MET/HGF therapies have not been able to demonstrate an improvement in OS [117] [118] [119] [120] . . Also, although there have been several studies of hyperthermic intraperitoneal chemotherapy (HIPEC) in Asia, including some indicating a survival advantage, the evidence is insufficient to recommend the incorporation of HIPEC into standard therapy [122] [123] [124] [125] [126] . The results of randomised trials of adjuvant HIPEC from Western centres are awaited. A study which retrospectively examined the outcomes of 277 patients who were treated with CRS plus HIPEC or CRS alone suggested a survival benefit in those patients treated with HIPEC. However, the fact the study was retrospective means it could potentially be biased [127] . The experts accepted completely [A ¼ 100%] 'recommendation 8b'.
Discussion Conclusions
The results of the voting by the Asian experts both before and after the face-to-face meeting in Kobe showed high concordance (supplementary Tables S1 and S2, available at Annals of Oncology online) with the ESMO recommendations for the treatment of patients with mGC published as part of the 2016 ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up for GC [18] . In terms of level of agreement there were no votes of less than an A (accept completely) following the face-to-face discussions, except for 'recommendation 4a-2'.
Thus, these guidelines can be considered to be consensus guidelines for the treatment of patients with mGC in Asia, with !80% of experts voting to accept completely or accept with reservation a specific recommendation. As mentioned previously, the levels of agreement provided by each of the Asian experts were based on the available scientific evidence and were independent of the approval and reimbursement status of certain drugs (including biologics) in their individual countries. A summary of the approval and reimbursement status of the recommended drugs, as of July 2018, is presented for each participating country Nivolumab not yet approved but available. Approved or reimbursed. Partially approved/reimbursed or with restriction.
Not approved or reimbursed.
5-FU, 5-fluorouracil; MCBS, Magnitude of Clinical Benefit Scale; S-1, tegafur/gimeracil/oteracil; FTD/TPI, trifluridine/tipiracil.
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